Acceleron is a biopharmaceutical company discovering, developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of red blood cells, bone, muscle, fat and the vasculature to treat musculoskeletal, metabolic and cancer-related diseases. Acceleron’s scientific approach takes advantage of its unique insight into the regenerative powers on the transforming growth factor-beta (TGF-β) superfamily of proteins.  Acceleron utilizes proven biotherapeutic technologies and capitalizes on the company’s internal GMP manufacturing capability to rapidly and efficiently advance its therapeutic programs. In September 2010, the Company signed a $498 million joint development and commercialization agreement with Shire on novel muscle therapeutics for orphan diseases.

Ed Kania is on the Board of Directors.